Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.155 USD | +1.30% | -6.43% | +44.25% |
Financials (USD)
Sales 2024 * | 26.34M | Sales 2025 * | 21.24M | Capitalization | 552M |
---|---|---|---|---|---|
Net income 2024 * | -139M | Net income 2025 * | -154M | EV / Sales 2024 * | 11.3 x |
Net cash position 2024 * | 254M | Net cash position 2025 * | 244M | EV / Sales 2025 * | 14.5 x |
P/E ratio 2024 * |
-4.17
x | P/E ratio 2025 * |
-4.04
x | Employees | 145 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.14% |
Latest transcript on C4 Therapeutics, Inc.
1 day | +1.39% | ||
1 week | -9.14% | ||
Current month | -26.68% | ||
1 month | -17.44% | ||
3 months | +56.92% | ||
6 months | +344.75% | ||
Current year | +42.48% |
Managers | Title | Age | Since |
---|---|---|---|
Andrew Hirsch
CEO | Chief Executive Officer | 53 | 20-09-13 |
Kendra Adams
DFI | Director of Finance/CFO | 48 | 20-11-19 |
Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bruce Downey
CHM | Chairman | 76 | 15-11-30 |
Glenn Dubin
BRD | Director/Board Member | 67 | 21-03-11 |
Bihua Chen
PRN | Corporate Officer/Principal | 55 | 15-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 8.143 | +1.16% | 392 629 |
24-03-27 | 8.05 | +1.39% | 1,742,395 |
24-03-26 | 7.94 | -3.29% | 1,814,659 |
24-03-25 | 8.21 | -0.12% | 1,284,465 |
24-03-22 | 8.22 | -5.63% | 1,192,855 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.48% | 552M | |
+9.16% | 45.97B | |
+53.86% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |